神經分泌生物科學 NBIX 深 滬
等待開盤 09-08 09:30:00 美东时间
155.64
-2.710
-1.71%
華盛通- 最 高159.7999
- 今 開158.24
- 成交量 93.36万股
- 最 低 154.83
- 昨 收 158.35
- 總市值 158.21亿
- 52周最高 186.12
- 市盈率 靜 33.33
- 換手率 0.92%
- 52周最低 122.1375
- 委 比 -89.61%
- 總股本 1.02亿
- 歷史最高 186.12
- 量 比 0.89
- 振 幅 3.14%
- 歷史最低 5.42
- 每 手 1
- 風險率 14.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 大行齐上调AI应用股目标价！Adobe、CRWD等获看好，慧与科技绩后现多空分歧
今日重点评级关注：BTIG：维持Climb Bio"买入"评级，目标价从20美元升至32美元；巴克莱：维持Alpha Tau Medical"超配"评级，目标价从17美元升至30美元
09-04 12:30
Citigroup Maintains Buy on Neurocrine Biosciences, Raises Price Target to $253
Citigroup analyst Yigal Nochomovitz maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $249 to $253.
09-04 00:28
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics announced its participation in several upcoming investor conferences in September 2026, including the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, Baird’s Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. A webcast of the Wells Fargo fireside chat will be available on Voyager’s website and archived for 30 days. The company fo...
09-01 12:00
Neurocrine Receives FDA Investigational New Drug Acceptance For NBI-1117567 Phase 2 Alzheimer's Study, Triggering $10M Payment To Nxera
NBI-1117567 is an investigational oral, muscarinic M1 preferring (M1/M4) selective agonist discovered by Nxera and advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive a US$10 million milestone payment upon IND Acceptance, as part of the overall...
08-26 15:55
Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'
On CNBC’s “Mad Money Lightning Round,” Jim Cramer recommended buying Uber Technologies, Inc. (NYSE:UBER), adding that it is one “great long-term” stock. According to recent news, Uber and drone delivery company Zipline announced a strategic partnership on Monday to expand autonomous delivery across ...
08-18 20:12
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
What's Going On With Neurocrine Biosciences Stock On Wednesday?
Neurocrine Biosciences Inc. (NASDAQ:NBIX) stock fell almost 5% on Wednesday before recovering after physicians and experts in Prader-Willi syndrome notified clinicians of some cases of deaths and severe complications potentially associated with Vykat XR (diazoxide choline). The San Diego-based compa...
08-12 23:57
Neurocrine slips as safety issues linked to Vykat XR resurface
Shares of Neurocrine Biosciences (NBIX) slipped in the premarket on Wednesday after safety concerns linked to Vykat XR, a rare disease therapy the company added with its acquisition of Soleno Therapeu...
08-12 19:29
Regeneron, Tenet leads top healthcare companies with highest earnings beats
As corporate earnings season progresses, investors are tracking sector performance metrics to gauge underlying healthcare demand and corporate efficiency. For the healthcare sector, spanning critical ...
08-12 18:54
